Relief Therapeutics appoints Drew Cronin-Fine as Head of U.S. Marketing

0 35

Relief Therapeutics announces the appointment of Drew Cronin-Fine as Executive Director, Head of U.S. Marketing, effective May 3, 2022.  The company stated that in this newly created position, Ms. Cronin-Fine will be responsible for building and leading the U.S. Marketing team. She will report to Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations.

Anthony Kim

Drew’s addition to the company reflects our continued commitment to building out our U.S. commercial team in anticipation of the rollout of PKU GOLIKE®, the flagship product line of our wholly owned subsidiary, APR Applied Pharma Research, SA (APR), and the upcoming June 5, 2022 Prescription Drug User Fee Act (PDUFA) date and potential launch of ACER-001 to treat Urea Cycle Disorders, in collaboration with Acer Therapeutics,” stated Mr. Kim.

He added, “Drew’s success in launching numerous products in the rare disease space, as well as her proven skills in digital technology and team building, gained from her tenures at Intercept Pharmaceuticals and Cubist Pharmaceuticals, make her a key member of the U.S. commercial team as we optimize our emerging rare disease pipeline.”

Drew Cronin-Fine

“My passion for improving the lives of patients with rare diseases, coupled with the opportunity to be part of the launch of potential new products in the U.S., were key factors that drew me to this exciting role at Relief Therapeutics,” added Ms. Cronin-Fine.

“I look forward to joining the emerging commercial team at Relief and being an integral part of its mission to develop therapeutics for serious diseases with few or no existing treatment options.”

She was responsible for directing the healthcare practitioner, patient, market access, and digital marketing initiatives at Intercept. Ms. Cronin-Fine worked at Cubist Pharmaceuticals (later bought by Merck) from 2012 to 2015, most recently as Associate Director, U.S. Marketing, where she handled market research, market access, and budget forecasting for ZERBAXA®, a gram-negative anti-infective drug.

Ms. Cronin-Fine spent the previous seven years at Intercept Pharmaceuticals, Inc., where she held various positions of increasing importance in U.S. Marketing. She headed the US marketing department for OCALIVA®, which is indicated for the treatment of primary biliary cholangitis, an orphan liver disease. 

Leave A Reply

Your email address will not be published.